Merck
MRK
Market cap $248B

98.05 USD

-1.47

1.48%

At close Dec 20, 4:00 PM EST

After hours

98.99

+0.94

0.96%

1 day

-1.48%

5 days

-3.16%

1 month

0.63%

3 months

-16.32%

6 months

-24.38%

Year to date

-13.41%

1 year

-6.94%

5 years

7.06%

10 years

66.30%

About: Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Employees: 72,000

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,809 funds

0

Analysts bullish %

of 11 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

10% more call options, than puts

Call options by funds: $1.95B | Put options by funds: $1.77B

8% more repeat investments, than reductions

Existing positions increased: 1,496 | Existing positions reduced: 1,389

2% less funds holding

Funds holding: 3,477 [Q2] → 3,415 (-62) [Q3]

3.0% less ownership

Funds ownership: 78.71% [Q2] → 75.7% (-3.0%) [Q3]

12% less capital invested

Capital invested by funds: $248B [Q2] → $218B (-$29.7B) [Q3]

30% less first-time investments, than exits

New positions opened: 145 | Existing positions closed: 207

42% less funds holding in top 10

Funds holding in top 10: 190 [Q2] → 111 (-79) [Q3]

See Fund Rankings

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$105

7%

upside

Avg. target

$127

29%

upside

High target

$155

58%

upside

11 analyst ratings

7 positive

64%

4 neutral

36%

0 negative

0%

BMO Capital Evan David Seigerman 24% 1-year accuracy 4 / 17 met price target	7%upside $105	Market Perform Downgraded	20 Dec 2024
B of A Securities Tim Anderson 50% 1-year accuracy 3 / 6 met price target	23%upside $121	Buy Reinstated	10 Dec 2024
Truist Securities Robyn Karnauskas 15% 1-year accuracy 4 / 27 met price target	33%upside $130	Buy Maintained	7 Nov 2024
Guggenheim Seamus Fernandez 54% 1-year accuracy 7 / 13 met price target	33%upside $130	Buy Maintained	6 Nov 2024
Wells Fargo Mohit Bansal 28% 1-year accuracy 7 / 25 met price target	12%upside $110	Equal-Weight Maintained	1 Nov 2024

See Analyst Rankings

Financial journalist opinion

Based on 64 articles about MRK published over the past 30 days

CNBC Television

Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture

The CNBC 'Halftime Report' Investment Committee discusses today's market movers.

Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture

Zacks Investment Research

MRK's Pivotal Study on Two-Drug, Once-Daily HIV Pill Meets Goals

Merck posts positive data from two phase III studies evaluating a two-drug, single-tablet regimen of doravirine/islatravir in adults with HIV-1 infection.

MRK's Pivotal Study on Two-Drug, Once-Daily HIV Pill Meets Goals

Zacks Investment Research

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know

The Motley Fool

Want to Collect a Dividend Every Month? Invest in These 3 High-Yielding Income Stocks

Collecting dividend income on a recurring basis can help strengthen your financial position and be a way for you to be less dependent on other sources of cash flow. The one downside is that many dividend stocks only pay on a quarterly basis, which means that you'll often be waiting multiple months before the next dividend payment.

Want to Collect a Dividend Every Month? Invest in These 3 High-Yielding Income Stocks

Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, from LaNova Medicines Ltd. As previously announced, Merck will develop, manufacture and commercialize LM-299. Merck will record a pre-tax charge relating to the upfront payment of $588 million, or approximately $0.18 per share, in the company's fourth quarte.

Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody

Stock Of The Day: Where Does The Merck Downtrend End?

Shares of Merck & Co., Inc. MRK are trading flat on Thursday, but remain in a downtrend.

Stock Of The Day: Where Does The Merck Downtrend End?

Zacks Investment Research

Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug

Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh Pharma.

Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug

24/7 Wall Street

Dow Losing Streak Longest in 50 Years: Grab These Bargain Blue-Chip Dividend Stocks Now

The Dow Jones industrial average is a price-weighted index of 30 blue-chip U.S.

Dow Losing Streak Longest in 50 Years: Grab These Bargain Blue-Chip Dividend Stocks Now

Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time

Merck & Co., a global pharmaceutical leader, focuses on oncology, immunology, and vaccines, with strong revenue from Keytruda and Gardasil despite challenges in China. Strategic acquisitions and partnerships, including Acceleron, Prometheus, and Daiichi Sankyo, bolster Merck's drug pipeline and expand its oncology and cardiovascular portfolios. Merck's robust R&D efforts and wide moat, supported by a strong dividend yield and A+ S&P credit rating, make it a compelling buy.

Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time

Merck's HIV treatment meets main goal of two late-stage studies

Merck said on Thursday its experimental drug combination to treat some adults with HIV-1 infection met the main goal of two late-stage studies.

Merck's HIV treatment meets main goal of two late-stage studies

See News Rankings

Charts implemented using Lightweight Charts™